Biosimulation Market Set for Strong Growth Through 2035, Fueled by AI-Driven Drug Discovery, Virtual Trials and Precision Medicine Demand
Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Biosimulation Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)" has been added to ResearchAndMarkets.com's offering.
The global biosimulation market reached USD 4.09 billion in 2025 and is projected to expand at a compound annual growth rate of 16.90% between 2026 and 2035. At this pace, the market is expected to attain USD 19.49 billion by 2035. Growth is being supported by rising pharmaceutical research and development expenditure, wider adoption of computational modelling, increasing demand for personalized medicine, and the need to improve the efficiency of drug discovery and clinical development.
Q1 2026 Biosimulation Market Update
The biosimulation market entered 2026 with a strong long-term outlook, although geopolitical instability involving the United States, Israel, and Iran has created near-term operational and supply chain challenges. Disruptions affecting Gulf-linked logistics and petrochemical supply have increased the cost of pharmaceutical packaging, active pharmaceutical ingredient precursors, reagents, and temperature-controlled transportation.
In the United States, petrochemical-derived packaging materials, including blister packs, polymer bottles, and specialty film coatings, are experiencing estimated cost increases of 15% to 20%. Similar inflation is affecting selected pharmaceutical reagents and active pharmaceutical ingredient inputs. Suspended or constrained Gulf carrier networks have also raised air freight costs and extended lead times for temperature-sensitive pharmaceutical products. Meanwhile, disruption at Middle Eastern clinical trial sites may delay data collection, regulatory submissions, and selected product launches.
Iran's healthcare and pharmaceutical sectors remain affected by damaged health facilities, power interruptions, workforce displacement, sanctions, and reduced access to medical technologies and pharmaceutical ingredients. These conditions have intensified pressure on hospital capacity and the availability of essential medicines and medical supplies.
Israel's pharmaceutical, biotechnology, and medical device industries are operating under emergency conditions, with healthcare resources prioritised for conflict-related needs. Despite these pressures, the country's biopharmaceutical research ecosystem continues to support novel therapeutic development. Post-conflict investment in healthcare infrastructure, medical technology, pharmaceutical capacity, and supply chain resilience could create new opportunities for the wider life sciences market.
Key Recommendations for Governments and Procurement Teams
Global Biosimulation Market Trends
Advances in computational power and software capabilities are improving the scale, speed, and accuracy of biosimulation platforms. Pharmaceutical and biotechnology companies are using these technologies to support dose selection, clinical trial design, safety assessment, pharmacokinetic analysis, and predictions of treatment response. These capabilities can shorten drug development timelines and reduce the financial exposure associated with unsuccessful clinical programmes.
The growing prevalence of chronic diseases is also increasing demand for predictive models that evaluate long-term therapeutic outcomes and support more efficient clinical trial design. In personalized medicine, biosimulation platforms are being applied to assess variations in drug response associated with patient characteristics, biomarkers, and genetic profiles. Applications are also expanding across disease modelling, toxicology, quantitative systems pharmacology, oncology, immunology, and pharmaceutical risk assessment.
Strategic acquisitions and platform launches continue to shape the competitive landscape. In December 2023, Certara acquired Applied BioMath to expand its quantitative systems pharmacology capabilities, including the prediction of optimal dosing regimens for novel therapies. In June 2023, Simulations Plus acquired Immunetrics in a transaction that included USD 15.5 million in cash, a USD 1.8 million holdback, and up to USD 8 million tied to revenue performance. The acquisition broadened the company's modelling expertise across oncology, immunology, and autoimmune diseases.
Certara also launched Simcyp Simulator Version 22 in March 2023, expanding the capabilities of its physiologically based pharmacokinetics platform. In January 2023, Cellworks introduced two business units focused on precision oncology drug testing, clinical trial optimization, biomarker development, and patient-response prediction.
Biosimulation Market Segmentation
By product and service, the global market is divided into software and services. Delivery models include subscription and ownership models, while major applications cover drug discovery, drug development, and additional research uses. Principal end users include pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other life sciences organizations.
Regional Market Outlook
North America leads the global biosimulation market due to its advanced healthcare infrastructure, concentration of major market participants, high pharmaceutical research expenditure, and rapid adoption of in-silico methods. The region's growing chronic disease burden and strong biotechnology sector are expected to sustain market expansion through 2035.
Asia Pacific is forecast to record substantial growth as governments and private organizations increase investment in healthcare infrastructure, pharmaceutical research, biotechnology, and digital technologies. Expanding clinical research activity and efforts to improve patient outcomes are expected to strengthen regional demand for biosimulation software and services.
Competitive Landscape
Competition in the global biosimulation market is intensifying as companies pursue mergers, acquisitions, product launches, partnerships, and research initiatives. Prominent participants include Certara, Simulations Plus, Advanced Chemistry Development, Physiomics, Genedata, Thermo Fisher Scientific, Immunetrics, BioSimulation Consulting, Yokogawa Insilico Biotechnology, and Chemical Computing Group. Continued innovation, broader therapeutic coverage, and integration with data analytics and artificial intelligence are expected to remain central to competitive growth.
Key Topics Covered:
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biosimulation Market Overview
3.1 Global Biosimulation Market Historical Value (2019-2025)
3.2 Global Biosimulation Market Forecast Value (2026-2035)
4 Global Biosimulation Market Landscape*
4.1 Global Biosimulation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biosimulation: Product Landscape
4.2.1 Analysis by Product and Services
4.2.2 Analysis by Delivery Model
4.2.3 Analysis by Applications
5 Global Biosimulation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter's Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biosimulation Market Segmentation (219-2035)
6.1 Global Biosimulation Market (2019-2035) by Product and Services
6.1.1 Market Overview
6.1.2 Software
6.1.2.1 Molecular Modeling and Simulation Software
6.1.2.2 PBPK Modeling and Simulation Software
6.1.2.3 Trial Design Software
6.1.2.4 Toxicity Prediction Software
6.1.2.5 Other Biosimulation Software
6.1.3 Services
6.1.3.1 In-House Services
6.1.3.2 Contract Services
6.2 Global Biosimulation Market (2019-2035) by Delivery Model
6.2.1 Market Overview
6.2.2 Subscription Model
6.2.3 Ownership Model
6.3 Global Biosimulation Market (2019-2035) by Application
6.3.1 Market Overview
6.3.2 Drug Discovery
6.3.2.1 Pre-Clinical Testing
6.3.2.2 Clinical Trials
6.3.3 Drug Development
6.3.3.1 Target Identification and Validation
6.3.3.2 Lead Identification and Optimization
6.3.4 Others
6.4 Global Biosimulation Market (2019-2035) by End User
6.4.1 Market Overview
6.4.2 Pharmaceutical and Biotechnology Companies
6.4.3 Contract Research Organization
6.4.4 Academic Research Institutes
6.4.5 Others
6.5 Global Biosimulation Market (2019-2035) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Biosimulation Market (219-2035)
7.1 North America Biosimulation Market (2019-2035) by Product and Services
7.1.1 Market Overview
7.1.2 Software
7.1.2.1 Molecular Modeling and Simulation Software
7.1.2.2 PBPK Modeling and Simulation Software
7.1.2.3 Trial Design Software
7.1.2.4 Toxicity Prediction Software
7.1.2.5 Other Biosimulation Software
7.1.3 Services
7.1.3.1 In-House Services
7.1.3.2 Contract Services
7.2 North America Biosimulation Market (2019-2035) by Application
7.2.1 Market Overview
7.2.2 Drug Discovery
7.2.2.1 Pre-Clinical Testing
7.2.2.2 Clinical Trials
7.2.3 Drug Development
7.2.3.1 Target Identification and Validation
7.2.3.2 Lead Identification and Optimization
7.2.4 Others
7.3 North America Biosimulation Market (2019-2035) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Biosimulation Market (219-2035)
8.1 Europe Biosimulation Market (2019-2035) by Product and Services
8.1.1 Market Overview
8.1.2 Software
8.1.2.1 Molecular Modeling and Simulation Software
8.1.2.2 PBPK Modeling and Simulation Software
8.1.2.3 Trial Design Software
8.1.2.4 Toxicity Prediction Software
8.1.2.5 Other Biosimulation Software
8.1.3 Services
8.1.3.1 In-House Services
8.1.3.2 Contract Services
8.2 Europe Biosimulation Market (2019-2035) by Application
8.2.1 Market Overview
8.2.2 Drug Discovery
8.2.2.1 Pre-Clinical Testing
8.2.2.2 Clinical Trials
8.2.3 Drug Development
8.2.3.1 Target Identification and Validation
8.2.3.2 Lead Identification and Optimization
8.2.4 Others
8.3 Europe Biosimulation Market (2019-2035) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Biosimulation Market (219-2035)
9.1 Asia Pacific Biosimulation Market (2019-2035) by Product and Services
9.1.1 Market Overview
9.1.2 Software
9.1.2.1 Molecular Modeling and Simulation Software
9.1.2.2 PBPK Modeling and Simulation Software
9.1.2.3 Trial Design Software
9.1.2.4 Toxicity Prediction Software
9.1.2.5 Other Biosimulation Software
9.1.3 Services
9.1.3.1 In-House Services
9.1.3.2 Contract Services
9.2 Asia Pacific Biosimulation Market (2019-2035) by Application
9.2.1 Market Overview
9.2.2 Drug Discovery
9.2.2.1 Pre-Clinical Testing
9.2.2.2 Clinical Trials
9.2.3 Drug Development
9.2.3.1 Target Identification and Validation
9.2.3.2 Lead Identification and Optimization
9.2.4 Others
9.3 Asia Pacific Biosimulation Market (2019-2035) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Biosimulation Market (219-2035)
10.1 Latin America Biosimulation Market (2019-2035) by Product and Services
10.1.1 Market Overview
10.1.2 Software
10.1.2.1 Molecular Modeling and Simulation Software
10.1.2.2 PBPK Modeling and Simulation Software
10.1.2.3 Trial Design Software
10.1.2.4 Toxicity Prediction Software
10.1.2.5 Other Biosimulation Software
10.1.3 Services
10.1.3.1 In-House Services
10.1.3.2 Contract Services
10.2 Latin America Biosimulation Market (2019-2035) by Application
10.2.1 Market Overview
10.2.2 Drug Discovery
10.2.2.1 Pre-Clinical Testing
10.2.2.2 Clinical Trials
10.2.3 Drug Development
10.2.3.1 Target Identification and Validation
10.2.3.2 Lead Identification and Optimization
10.2.4 Others
10.3 Latin America Biosimulation Market (2019-2035) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Biosimulation Market (219-2035)
11.1 Middle East and Africa Biosimulation Market (2019-2035) by Product and Services
11.1.1 Market Overview
11.1.2 Software
11.1.2.1 Molecular Modeling and Simulation Software
11.1.2.2 PBPK Modeling and Simulation Software
11.1.2.3 Trial Design Software
11.1.2.4 Toxicity Prediction Software
11.1.2.5 Other Biosimulation Software
11.1.3 Services
11.1.3.1 In-House Services
11.1.3.2 Contract Services
11.2 Middle East and Africa Biosimulation Market (2019-2035) by Application
11.2.1 Market Overview
11.2.2 Drug Discovery
11.2.2.1 Pre-Clinical Testing
11.2.2.2 Clinical Trials
11.2.3 Drug Development
11.2.3.1 Target Identification and Validation
11.2.3.2 Lead Identification and Optimization
11.2.4 Others
11.3 Middle East and Africa Biosimulation Market (2019-2035) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Certara Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Dassault Systemes
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Simulation Plus
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Schrodinger Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Advanced Chemistry Development Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Physiomics PLC
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Genedata AG
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Thermo Fisher Scientific
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Immunetrics
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 BioSimulation Consulting Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Yokogawa Insillico Biotechnology GmbH
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Chemical Computing Group ULC
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
18 Global Biosimulation Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
Companies Featured
For more information about this report visit https://www.researchandmarkets.com/r/97r3x7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.